Clinical trials · Texas
IgA Nephropathy clinical trials in Texas
We’re tracking 9 recruiting iga nephropathy studies with a site in Texas — including Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06712407RecruitingPhase 4
Extended TARPEYO treatment for IgA nephropathy
This study tests whether taking TARPEYO (budesonide) for longer than 9 months is safe and effective for adults with IgA nephropathy. It's for people who have already completed a 9-month course of TARPEYO and are on stable blood pressure medication.
Houston, TexasAges 18 years+ - NCT07054684RecruitingPhase 1
Study of BHV-1400 for IgA Nephropathy
This trial tests a new medicine, BHV-1400, for people with IgA Nephropathy, a kidney disease. The goal is to see if it can help slow down kidney damage.
Houston, TexasAges 18–65 - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Houston, TexasAges 18–60 - NCT06740526RecruitingPhase 2
A trial of sibeprenlimab for IgA nephropathy kidney tissue
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
Houston, TexasAges 16 years+ - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Dallas, TexasAges 18–100 - NCT06963827RecruitingPhase 3
Study of mezagitamab for IgA nephropathy
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Dallas, TexasAges 18 years+ - NCT06989359RecruitingPhase 2
Study of ADX-038 for complement-related kidney disease
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Dallas, TexasAges 18 years+ - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Houston, TexasAges 1–17 - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Houston, TexasAges 18–99
IgA Nephropathy trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting iga nephropathy studies listed above.
- Dallas Renal Group · 3 studies
- Prolato Clinical Research Center · 2 studies
- ADARx Clinical Site
- Dallas Nephrology Associates McKinney
- DCR - El Paso
- Dermatology Clinical Research Center of San Antonio
- El Paso Medical Research Institute (Medresearch Inc)
- Houston Methodist Hospital
What taking part in a iga nephropathy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
IgA Nephropathy trials in other states
Common questions
- Are there iga nephropathy clinical trials in Texas?
- Yes. We're currently tracking 9 recruiting iga nephropathy studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a iga nephropathy study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a iga nephropathy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New iga nephropathy studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.